Diana N. Ionescu, MD, FRCP(C), FCAP

Consultant Pathologist, BC Cancer Agency
Medical Director Clinical Trials, BCCA VCC Laboratory
Clinical Professor, Department of Pathology and Laboratory Medicine, UBC
Vancouver, BC

Dr. Ionescu is a graduate of University of Medicine and Pharmacy “Iuliu Hatieganu” in Cluj Napoca, Romania. She completed her postgraduate training in Anatomical and Clinical Pathology at the University of Pittsburgh Medical Center and a Fellowship in Gynecological Pathology at Vancouver General Hospital. She has practiced as a Consultant Pathologist at BC Cancer Agency in Vancouver since 2006. She is currently a Clinical Professor of Pathology at UBC and served as the residency program director for the Anatomic Pathology Residency Program between 2009 – 2017.

Her specific areas of diagnostic expertise are lung, gynecologic and breast pathology. She is an author of over 35 scientific publications and book chapters. She is the author and invited speaker at numerous regional, national and international lectures. Her investigation interests include oncologic pathology and molecular biomarkers, lung cancer and adult health education. She is the Canadian Anatomic and Molecular Pathology (CAMP) course director.

Dr. Ionescu is an enthusiastic advocate of pathologists participating in numerous patient education forums, TV shows, advocacy campaigns, being an Medical Advisor for Lung Cancer Canada and in 2015 appeared before the House of Commons Committee on Health.


Kim Chi, MD, FRCP(C)

Medical Oncologist, BC Cancer Agency
Director, Clinical Research, BC Cancer Agency
Professor, Department of Medicine, UBC
Vancouver, BC

Dr. Kim Chi is a medical oncologist and Regional Medical Director BC Cancer Agency – Vancouver Cancer Centre, Vancouver, Canada. He is also a Professor of Medicine at the University of British Columbia, Medical Director for Clinical Trials at the Vancouver Cancer Centre, Director of Clinical Research for the BC Cancer Agency, and the Co-Director of Clinical Research at the Vancouver Prostate Centre. Dr. Chi is also the Co-Chair of the Genitourinary Disease Site Committee for the Canadian Cancer Trials Group (CCTG) and the Co-Chair for the Canadian Uro-Onology Group (CUOG). Dr. Chi’s research is in the area of genitourinary cancers with a focus in prostate cancer and investigational new drugs.  This includes outcomes, phase I-III clinical trials, neoadjuvant studies and mechanisms of treatment resistance. He has had peer-reviewed grant funding from the Canada Institutes of Health Research (CIHR), National Cancer Institute of Canada (NCIC)/Canadian Cancer Society (CCS), the US Department of Defense, Movember and the Prostate Cancer Research Foundation of Canada.

Andrew Churg, MD

Professor of Pathology, University of British Columbia
Pathologist, Vancouver General Hospital
Vancouver, BC.

Andrew Churg, MD, is Professor of Pathology at the University of British Columbia and a pathologist at Vancouver General Hospital.  He is the author of more than 400 journal articles, book chapters, and books that deal with all aspects of lung and pleural pathology. He is the Chairman of the US-Canadian Mesothelioma Reference Panel.  His particular interests are pathology of interstitial lung disease, and the diagnosis of malignant mesothelioma.

Malcolm Hayes, MD, BSc, MB,ChB, LRCP, MRCS, M.Med. Path, FRCPath, FRCPC

Clinical Professor of Pathology and Laboratory Medicine
University of British Columbia
Pathologist, BCCA
Vancouver, BC

Malcolm Hayes is a pathologist at the BC Cancer Agency (BCCA) in Vancouver. Dr. Hayes has worked at the BCCA since 1993 and has broad expertise in surgical pathology and cytopathology and major interests in breast, skin, gynecological and soft tissue pathology. He is a Clinical Professor of pathology at the University of British Columbia and a Fellow of the Royal College of Pathologist of UK. He has many years of expertise in diagnostic immunohistochemistry based on employment of this technique in the work up of a large volume of challenging consultation cases referred to the BCCA “Primary Unknown” tumour group.

David Huntsman, MD, FRCPC, FCCMG

Dr. Chew Wei Memorial Professor of Gynaecologic Oncology
UBC Professor, Departments of Pathology and Lab Medicine and Obstetrics and Gynaecology
UBC Director of OvCaRe, Vancouver General Hospital, BC Cancer Agency
UBC Distinguished Scientist, Department of Molecular Oncology
BC Cancer Agency Research Centre Canada Research Chair in Molecular and Genomic Pathology
Vancouver, BC

Dr. David Huntsman is the Dr. Chew Wei Memorial Professor of Gynaecologic Oncology, holds the Canada Research Chair (Tier 1) in Molecular and Genomic Pathology, and is a Professor in the Departments of Pathology & Laboratory Medicine and Obstetrics & Gynaecology at The University of British Columbia. He is a Staff Pathologist at the BC Cancer Agency and a Consulting Pathologist at the Vancouver General Hospital.

Dr. Huntsman attended medical school at Memorial University of Newfoundland from 1984-88 and after completing a rotating internship, practiced family medicine in Labrador for two years. Following his experience in family medicine, he entered and completed a pathology residency and trained in clinical molecular genetics at UBC and subsequently studied cancer genetics at Cambridge University, UK.

Dr. Huntsman is a co-founder and Director of BC’s Ovarian Cancer Research (OVCARE) Program, where he leads a multidisciplinary team of over 50 scientists, staff and trainees in the study of ovarian and other gynaecological cancers. He is also co-Director of the Genetic Pathology Evaluation Centre (GPEC) at the Jack Bell Research Centre, VGH and former Medical Director of the Centre for Translational and Applied Genomics (CTAG) at the BCCA.

Dr. Huntsman’s research has led to the development of predictive and prognostic tissue-based cancer biomarkers for ovarian cancer and a wide variety of other tumour types. His team created a blueprint for histotype specific ovarian cancer control and have been leaders in the application of novel genomics technologies to ovarian cancer.

Recently, his team applied next generation sequencing technologies to ovarian cancers and discovered key mutations in granulosa cell tumours, clear cell and endometrioid carcinomas, sertoli-leydig cell tumours of the ovary and small cell carcinomas of the ovary. His team is working to determine the biologic and clinical relevance of these discoveries with a view to developing new treatment, diagnostic and prevention opportunities.

Dr. Huntsman is the recipient of numerous awards including the prestigious William E. Rawls Prize for contributions to advances in cancer control in Canada (2014), the Gerald Award for Translational Research and Pathology from the Memorial Sloan Ketter Cancer Center (2016), the Karen Campbell National Award for Excellence in Ovarian Cancer Research (Feb 2012), the Killam Research Prize and Overall Excellence Senior Faculty Award from the UBC Faculty of Medicine (2012), and the inaugural Virginia Greene leadership award for ovarian cancer research and advocacy (Sept 2011).

Cheng-Han Lee, MD, PhD, FRCPC

Clinical Assistant Professor
University of British Columbia
Medical Director, Department of Pathology & Laboratory Medicine
British Columbia Cancer Agency
Vancouver, BC

Dr. Lee received his MD-PhD degree from the University of British Columbia (UBC) in 2004 and completed his Anatomic Pathology residency training (UBC) in 2009.  His interest in cancer genetics led him to pursue research fellowships at Stanford University Medical Center and Brigham and Women’s Hospital, where he studied the genetic basis and biology of high-grade endometrial stromal sarcoma.  His work led to the recognition of a new disease entity that was subsequently adopted in the 2014 WHO classification system for tumors of the female reproductive system. More recently, Dr. Lee has applied various next generation sequencing methods and high-throughput assays to gain clinically and diagnostically informative insights into epithelial/mesenchymal tumors of the uterus, including the most aggressive subtypes of uterine cancer such as dedifferentiated endometrial cancer, carcinosarcoma as well as a number of uterine sarcoma types.

Dr. Lee currently has over 100 peer-reviewed publications and a number of book chapters, and is the recipient of a number of young investigator/junior scientist awards from both national and international organizations.  He is currently a consultant pathologist and the medical director of the department of Pathology and Laboratory Medicine at British Columbia Cancer Agency. His subspecialty practice interests are in gynecologic, bone/soft tissue and molecular pathology.

Tony Ng, MD, PhD, FRCPC

Clinical Assistant Professor, Pathology and Laboratory Medicine,
University of British Columbia
Consultant Head and Neck Pathologist, Vancouver General Hospital
Vancouver, BC

Dr. Tony Ng is a consultant pathologist at the Vancouver General Hospital and the British Columbia Cancer Agency, with a subspecialty practice in sarcoma pathology and head and neck pathology. He is also a clinical assistant professor at the University of British Columbia, and the Anatomical Pathology residency program site director at the Vancouver General Hospital. Dr. Ng received his MD and completed his Anatomical Pathology residency at the University of British Columbia, with subsequent surgical pathology fellowship training at Stanford University. He also concurrently completed his PhD in molecular oncology and cell biology in Dr. Poul Sorensen’s laboratory at the BC Cancer Research Center. His research interests are in cancer genomics, particularly in relation to molecular diagnostics for fusion gene-associated cancers such as sarcomas, and the incorporation of next-generation genomic findings into surgical pathology practice.

Brian D. Robinson, M.D.

Chief of Surgical Pathology
Co-Chief, Urologic Pathology
Assistant Professor of Pathology & Laboratory Medicine Assistant Professor of Pathology in Urology
Weill Cornell Medicine
Department of Pathology & Laboratory Medicine
New York, NY

Dr. Robinson received his Doctor of Medicine from Weill Cornell Medical College, and he completed his residency training in Anatomic Pathology at New York-Presbyterian Hospital/Weill Cornell Medical Center.  He then moved to The Johns Hopkins Hospital for a clinical and research fellowship in Urologic Pathology. After fellowship training, he returned to Weill Cornell as a faculty member, and his clinical and research activities focus on diseases of the genitourinary tract.  He serves as Chief of Surgical Pathology and Co-Chief of Urologic Pathology at Weill Cornell, and he is a member of the medical center’s Englander Institute for Precision Medicine.

Dr. Robinson has co-authored more than 90 peer-reviewed publications, written over a dozen textbook chapters, and edited an upcoming textbook on the molecular pathology of prostate cancer.  He serves on several expert panels for prostate, bladder, and upper urinary tract malignancies, and he sits on the Editorial Board for the Precision Medicine Section of Archives of Pathology & Laboratory Medicine.  In addition to his clinical and research activities, he is active in medical student education and serves as Pathology Director for the Cornell medical student’s pathophysiology course.

Kiril Trpkov, MD, FRCPC

Surgical Pathologist, Professor of Pathology
Genitourinary Pathology Group Leader
Department of Pathology and Laboratory Medicine,
University of Calgary
Calgary Laboratory Services, Rockyview General Hospital
Calgary, AB

Dr. Kiril Trpkov is a Full Professor of Pathology at the University of Calgary, Alberta, Canada. He is one of the leading Canadian uropathologists and he is a consultant for the Calgary Laboratory Services, Southern Alberta Institute of Urology and the Tom Baker Cancer Center in Calgary, Canada. He is also a Genitourinary (GU) Pathology Group Leader for the Calgary Laboratory Services, Chair of the provincial GU Pathology Special Interest Group and a member of the provincial GU cancer team.

Dr. Trpkov has established the Anatomical Pathology Laboratory at the Rockyview General Hospital in Calgary, Alberta as of the largest centralized uropathology centres in Canada and North America. He has published over 100 peer-reviewed articles, numerous book chapters and other scholarly contributions. Dr. Trpkov has conducted many courses, workshops and slide seminars in uropathology and he has given lectures on all continents (excluding the Antarctica!). He is currently involved as a uropathology expert with several national and international expert panels which establish guidelines in uropathology and prostate cancer. Dr. Trpkov has received several awards for his work. In 2013, he has been awarded the Grawitz Medal for his outstanding contributions to the International Society of Urologic Pathology.

Stephen Yip MD, PhD, FRCPC

Neuropathologist, Vancouver General Hospital
Associate Professor of Medicine, University of British Columbia
Vancouver, BC

Stephen Yip completed his MD-PhD training at UBC followed by 4/6 years of neurosurgery residency when he decided to switch to neuropathology. He did his fellowship training at the Massachusetts General Hospital under the mentorships of David Louis and John Iafrate. Stephen Yip is a contributor to the 2016 WHO Classification of CNS Tumours. In 2012, I discovered recurrent mutations in CIC in a majority of 1p19q-codeleted, IDH mutated oligodendroglioma. He is collaborating with Marco Marra in the Personalized OncoGenomics (POG) program of which he is the lead pathologist and is also branching out to large-scale epigenomics and proteomic investigations.


Clinical Molecular Geneticist, Cancer Genetics & Genomics Laboratory
BC Cancer Agency
Clinical Associate Professor, Dept of Pathology and Laboratory Medicine
University of British Columbia
Vancouver, BC

Dr Young is a Clinical Molecular Geneticist in the Cancer Genetics and Genomics Laboratory, BC Cancer.  He completed his undergraduate studies in Biochemistry at the University of Waterloo (1992), a Master’s degree in Chemistry (Laurentian, 1995) and doctoral studies at the University of Ottawa in human molecular genetics under the supervision of Dr Robert Korneluk (2000). Following his doctoral studies Dr Young was certified as a Clinical Molecular Geneticist by both the American Board of Medical Genetics (ABMG, 2005) and the Canadian College of Medical Geneticists (CCMG, 2006).  Dr Young has served on the Board of Directors, the Molecular Examinations committee, and the Credentials Committed of the latter.

As a Clinical Molecular Geneticist, Dr Young has been involved in the results interpretation and reporting of the bulk of molecular genetic tests stemming from Cancer Genetics Laboratory at BC Cancer.  He is also a member of the ethics committee of the Personalized Onco-Genomics Program (POG) and is responsible for clinical interpretation of germline variants identified through this project. His main interests lie in molecular genetic service delivery, molecular monitoring, and the development/adoption of new tests and testing paradigms.